Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biovaxys Technology Corp (OP:BVAXF)

0.0232 -0.0005 (-2.11%)
Streaming Delayed Price Updated: 2:35 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biovaxys Technology Corp

< Previous 1 2 Next >
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D
Via FinancialNewsMedia
Topics Death
Exposures Death
BIOVAXYS CANCER VACCINE MANUFACTURING PARTNER BIO ELPIDA REACHES BIOPRODUCTION MILESTONE
Via FinancialNewsMedia
Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President’s New OSHA Mandates
Via FinancialNewsMedia
Exposures COVID-19
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
Via FinancialNewsMedia
Exposures COVID-19
BIOVAXYS BIOPRODUCTION PARTNER WUXI BIOLOGICS COMPLETES SYNTHESIS OF RECOMBINANT SARS-COV-2 S-PROTEINS FOR BVX-0320 AND CoviDTH PROGRAMS
Via FinancialNewsMedia
Exposures COVID-19
FURTHER STUDY IN HUMANS SHOWS THAT THE DTH RESPONSE, THE BASIS FOR CoviDTH, IS HIGHLY DURABLE AND PERSISTS FOR AT LEAST ONE YEAR AFTER COVID-19 EXPOSURE OR VACCINE ADMINISTRATION
Via FinancialNewsMedia
Exposures COVID-19
Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
FDA PROVIDES NECESSARY GUIDANCE FOR BIOVAXYS TO BEGIN PREPARATION OF IND FOR PHASE I/II CLINICAL TRIALS OF CoviDTH
Via FinancialNewsMedia
Exposures Product Safety
BIOVAXYS ANNOUNCES APPOINTMENT OF POLICY ADVISOR
Via FinancialNewsMedia
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases
Via FinancialNewsMedia
Exposures COVID-19
BIOVAXYS AND BIOELPIDA SIGN DEFINITIVE EXCLUSIVE AGREEMENT TO BEGIN OVARIAN CANCER VACCINE BIOPRODUCTION
Via FinancialNewsMedia
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.